Literature DB >> 17489656

Design of fine particles for pulmonary drug delivery.

Jeffry G Weers1, Thomas E Tarara, Andrew R Clark.   

Abstract

Particle design for inhalation is characterized by advances in particle processing methods and the utilization of new excipients. Processing methods such as spray drying allow control over critical particle design features, such as particle size and distribution, surface energy, surface rugosity, particle density, surface area, porosity and microviscosity. Control of these features has enabled new classes of therapeutics to be delivered by inhalation. These include therapeutics that have a narrow therapeutic index, require a high delivered dose, and/or elicit their action systemically. Engineered particles are also being utilized for immune modulation, with exciting advances being made in the delivery of antibodies and inhaled vaccines. Continued advances are expected to result in 'smart' therapeutics capable of active targeting and intracellular trafficking.

Mesh:

Substances:

Year:  2007        PMID: 17489656     DOI: 10.1517/17425247.4.3.297

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  13 in total

1.  New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.

Authors:  Christophe Duret; Nathalie Wauthoz; Thami Sebti; Francis Vanderbist; Karim Amighi
Journal:  Pharm Res       Date:  2012-05-30       Impact factor: 4.200

2.  One-step production of protein-loaded PLGA microparticles via spray drying using 3-fluid nozzle.

Authors:  Feng Wan; Morten Jonas Maltesen; Sune Klint Andersen; Simon Bjerregaard; Camilla Foged; Jukka Rantanen; Mingshi Yang
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

Review 3.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

4.  Pharmaceutical microparticle engineering with electrospraying: the role of mixed solvent systems in particle formation and characteristics.

Authors:  Adam Bohr; Feng Wan; Jakob Kristensen; Mark Dyas; Eleanor Stride; Stefania Baldursdottír; Mohan Edirisinghe; Mingshi Yang
Journal:  J Mater Sci Mater Med       Date:  2015-01-29       Impact factor: 3.896

5.  A Design of Experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose/leucine formulations with application in pulmonary delivery.

Authors:  S Focaroli; P T Mah; J E Hastedt; I Gitlin; S Oscarson; J V Fahy; A M Healy
Journal:  Int J Pharm       Date:  2019-03-05       Impact factor: 5.875

Review 6.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Authors:  David E Geller; Jeffry Weers; Silvia Heuerding
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-03-11       Impact factor: 2.849

7.  Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.

Authors:  Yoen-Ju Son; P Worth Longest; Michael Hindle
Journal:  Int J Pharm       Date:  2013-01-10       Impact factor: 5.875

8.  Study of the RESS process for producing beclomethasone-17,21-dipropionate particles suitable for pulmonary delivery.

Authors:  Paul A Charpentier; Ming Jia; Rahima A Lucky
Journal:  AAPS PharmSciTech       Date:  2008-01-08       Impact factor: 3.246

9.  Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery.

Authors:  Susan Hoe; James W Ivey; Mohammed A Boraey; Abouzar Shamsaddini-Shahrbabak; Emadeddin Javaheri; Sadaf Matinkhoo; Warren H Finlay; Reinhard Vehring
Journal:  Pharm Res       Date:  2013-08-23       Impact factor: 4.200

10.  Pretreatment with inhaled procaterol improves symptoms of dyspnea and quality of life in patients with severe COPD.

Authors:  Hiroyuki Ohbayashi; Mitsuru Adachi
Journal:  Int J Gen Med       Date:  2012-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.